NEW YORK (360Dx) – Oxford Immunotec reported Tuesday that its second quarter revenues increased 36 percent year over year, driven by continued growth in both its tuberculosis and tick-borne disease testing franchises.

For the three months ended June 30, Oxford Immunotec reported total revenues of $26.1 million, up from $19.2 million a year ago, and beating analysts' average estimate of $25.1 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.